04.

News

Find out the latest news about NextCell
2020-08-03

NextCell announces Eurostars grant for developing an innovative cell therapy production platform

NextCell Pharma AB (“NextCell” or the “Company”) announces today that the Company together with 3 partner organizations have been awarded a €1.6M Eurostars grant of which NextCell’s share is €470,000. The aim of the project entitled Bioscale, is to optimise automated bioreactors to manufacture th...
Read more
2020-07-31

NextCell Pharma AB publishes its interim report for September 2019 - May 2020

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - May 31, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report Nine months (2019-09-01 until 2020-05-31) · Operating income amounted...
Read more
2020-07-06

NextCell approved for trading on Nasdaq First North

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading on Spotlight is Tuesday, July 21, 2020 and the first day for trading on Nasdaq First North is Wedne...
Read more
2020-06-24

NextCell Pharma AB’s rights issue heavily oversubscribed

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees hav...
Read more
2020-06-09
NextCell's phase II study is completed – a phase III is being prepared
NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented dur...
Read more
2020-06-03
NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of ...
Read more
2020-05-28
Invited to panel discussion; Post-Covid-19 world
NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join ...
Read more
2020-05-15
The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue
NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approv...
Read more
2020-04-29
NextCell Pharma AB publishes its interim report for September 2019 - February 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income...
Read more
2020-03-20
NextCell in discussions about patients with covid-19
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this informa...
Read more
2020-03-11
The stem cell company NextCell Pharma is preparing for a pivotal phase III trial
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (...
Read more
2020-02-21
The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to...
Read more

News

15/6/2020
Interview with the CEO in Biostock
NextCell Pharma wants to rethink the treatment paradigm for diabetes.
Read more
10/6/2020
Article about NextCell Pharma in Biostock
NextCell Pharma will pass several milestones via share issue
Read more
6/5/2020
Interview with NextCell Pharma's CEO Mathias Svahn
Our fully recruited Phase 2-study is almost finished and we see no risk for delays despite the current pandemic. The results are as expected for Q3.
Read more
6/4/2020
The stem cell treatment that could stop diabetes
Diabetes is increasing among children and young people. Today the disease is incurable, but the stem cell company NextCell Pharma believes that diabetes and several other diseases could be treated with stem cells.
Read more

Company Presentations

Ladda ner

Aktiespararnas aktiedag, 2020-05-04

CEO Mathias Svahn presents the company (in Swedish)
Ladda ner

Elevator Pitch

A short video where CEO Mathias Svahn introduces the company

Company Analyses

6/17/2019
Analyst Group
Bull & Bear-Analysis
New capital enables completion of Phase I/II
Read more
6/13/2019
SvD Näringsliv
Nextcell Pharma: A rare investment opportunity
The stem cell company NextCell is currently issuing new shares to finance the ongoing development of their drug candidate ProTrans. (Article in Swedish)
Read more
8/10/2018
Analyst Group
Bull & Bear-Analysis
Unique stem cell company with potential within several diseases
Read more